Table 4.
Associations between patient characteristics and chemotherapy toxicities, after overlap weighting
| Univariate analysis | Multivariate analysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderate toxicities | Severe toxicities | Moderate toxicities | p | Severe toxicities | p | |||||||
| Variable& | OR | 95%CI | p | OR | 95%CI | p | OR | 95%CI | OR | 95%CI | ||
| Female sex | 0.88 | 0.51-1.49 | .63 | 0.86 | 0.49-1.50 | .59 | ||||||
| >80 years of age | 0.79 | 0.46-1.35 | .38 | 0.95 | 0.54-1.68 | .87 | ||||||
| Metastatic status | 0.91 | 0.54-1.55 | .74 | 1.06 | 0.61-1.86 | .83 | ||||||
| ECOG-PS > 1 | 1.37 | 0.80-2.35 | .25 | 1.68 | 0.96-2.94 | .07 | 1.12 | 0.62-2.01 | .71 | 1.26 | 0.68-2.33 | .46 |
| Polychemotherapy | 1.38 | 0.82-2.33 | .23 | 1.14 | 0.66-1.98 | .63 | ||||||
| Hemoglobin < 10 g/dl | 1.82 | 0.75-4.38 | .19 | 3.45 | 1.46-8.14 | .005 | 1.78 | 0.71-4.47 | .22 | 2.96 | 1.20-7.29 | .02 |
| Creatine clearance rate < 30 mL/minute | 1.48 | 0.33-6.55 | .49 | 2.80 | 0.68-11.56 | .15 | 1.40 | 0.31-6.32 | .66 | 2.42 | 0.56-10.33 | .23 |
| Albuminemia < 35 g/L | 0.98 | 0.57-1.69 | .94 | 1.49 | 0.85-2.61 | .16 | 0.78 | 0.43-1.40 | .40 | 1.03 | 0.56-1.89 | .93 |
| 6-month weight loss | 1.45 | 0.77-2.75 | .25 | 1.43 | 0.74-2.77 | .29 | ||||||
| CIRS-G > 12 | 1.58 | 0.86-2.90 | .14 | 1.87 | 1.00-3.48 | .05 | 1.51 | 0.80-2.85 | .20 | 1.62 | 0.84-3.14 | .15 |
| ADL < 6 | 1.18 | 0.54-2.61 | .68 | 1.32 | 0.59-2.97 | .50 | ||||||
| IADL < 7 | 1.14 | 0.67-1.96 | .63 | 1.39 | 0.80-2.43 | .25 | ||||||
| TUG < 20 s | 0.52 | 0.25-1.05 | .07 | 0.56 | 0.26-1.16 | .12 | 0.53 | 0.25-1.11 | .09 | 0.65 | 0.30-1.42 | .28 |
| Cognitive impairment | 0.89 | 0.45-1.76 | .74 | 1.20 | 0.61-2.38 | .59 | ||||||
| BMI <22 vs 22-25 kg/m2 >25 vs 22-25 kg/m2 |
1.12 1.34 |
0.57-2.22 0.72-2.49 |
.74 .36 |
1.27 1.17 |
0.62-2.56 0.61-2.26 |
.51 .63 |
||||||
| Gynaecological cancer* | 0.87 | 0.45-1.68 | .69 | 0.73 | 0.37-1.46 | .38 | ||||||
| GU cancer* | 1.14 | 0.46-2.82 | .77 | 1.34 | 0.54-3.34 | .52 | ||||||
| Lung cancer* | 0.98 | 0.34-2.79 | .97 | 0.84 | 0.28-2.55 | .76 | ||||||
| Other cancer* | 0.73 | 0.33-1.64 | .45 | 0.67 | 0.29-1.55 | .35 | ||||||
&For continuous variables, the Youden Index30 was used to identify the cutoff with the highest sensitivity and specificity for classifying the presence or absence of toxicity. Variables with P < .1 in the univariate analysis and clinically relevant variables (single-agent chemotherapy or combination chemotherapy) were examined further in a multivariate logistic regression model.
*Reference: digestive cancer.
Abbreviations: ADL, Activities of Daily Living; BMI, body mass index; CIRS-G, Cumulative Illness Rating Scale for Geriatrics; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; GU, genito-urinary; IADL, Instrumental Activities of Daily Living; TUG, timed up-and-go.